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Abstract
Polyunsaturated fatty acids (PUFAs) form an important constituent of all the cell membranes in the
body. PUFAs such as arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) form precursors to both pro-inflammatory and anti-inflammatory compounds. Low-grade
systemic inflammation occurs in clinical conditions such as insulin resistance, hypertension, type 2
diabetes mellitus, atherosclerosis, coronary heart disease, lupus, schizophrenia, Alzheimer's
disease, and other dementias, cancer and non-alcoholic fatty liver disease (NAFLD) that are also
characterized by an alteration in the metabolism of essential fatty acids in the form of excess
production of pro-inflammatory eicosanoids and possibly, decreased synthesis and release of anti-
inflammatory lipoxins, resolvins, protectins and maresins. We propose that low-grade systemic
inflammation observed in these clinical conditions is due to an imbalance in the metabolism of
essential fatty acids that is more in favour of pro-inflammatory molecules. In this context, transgenic
fat-1 mouse that is designed to convert n-6 to n-3 fatty acids could form an ideal model to study
the altered metabolism of essential fatty acids in the above mentioned conditions. It is envisaged
that low-grade systemic inflammatory conditions are much less likely in the fat-1 mouse and/or
these diseases will run a relatively mild course. Identifying the anti-inflammatory compounds from
n-3 fatty acids that suppress low-grade systemic inflammatory conditions and understanding their
mechanism(s) of action may lead to newer therapeutic strategies.
Introduction
One traditional approach to modify tissue nutrient com-
position to study the effects of different diets is by supple-
menting the experimental groups with different diets
consisting of many variations. Although this is an
accepted mode of studying the effect of various nutrients
and their effects on various physiological processes and
pathologic situations, it is difficult to make all the dietary
components identical, except the total energy, between
two diets and perhaps the single component in which one
is interested. The inevitable differences between diets and
their components, however small they may be, may con-
found the study and contribute to inconsistencies or con-
flicting results observed. This is especially so for studies
when one wishes to know the specific actions and func-
tions of ω-3 and ω-6 fatty acids. In general, the effects of
ω-3 and ω-6 fatty acids are studied supplementing the
experimental groups of animals with different ω-3/ω-6
fatty acid ratios to establish the different fatty acid profiles
in the tissues and extrapolate the results so obtained to the
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observed differences in the indices examined. In these
studies, generally, fish oils and plant seed/vegetable oils
are used to provide the required ω-3/ω-6 fatty acids
respectively. Since these fatty acids are derived from differ-
ent sources and are likely to contain other bioactive com-
pounds, however minor they might be, are likely to affect
the study outcomes. Furthermore, polyunsaturated fatty
acids (PUFAs) are highly unstable and susceptible to oxi-
dation. These variables arising from the diet and feeding
procedures invariably affect the results.
Fat-1 mouse
In view of these issues, it is ideal to develop a transgenic
mouse capable of converting ω-6 to ω-3 fatty acids so that
the results obtained in such an animal model will be more
reliable and easy to interpret in terms of the effects of ω-3
and ω-6 fatty acids. Mice engineered to carry fat-1 gene
from Caenorhabditis elegans can add a double bond into an
unsaturated fatty acid hydrocarbon chain and convert ω-6
to ω-3 fatty acids as shown in Figure 1. This resulted in an
abundance of ω-3 and a reduction in ω-6 fatty acids in the
organs and tissues of these mice even in the absence of
dietary ω-3 fatty acids [1]. Thus, fat-1 mouse model offers
an opportunity for investigating the biological functions
of ω-3 fatty acids and the importance of the ratio of ω-3/
ω-6 in various physiological processes and diseases. When
both transgenic and wild type mice were maintained on a
diet rich in ω-6 fatty acids (mainly linoleic acid, 18:2)
with very little ω-3 fatty acids (~ 0.1% of total fat sup-
plied), wild type mice showed little or no ω-3 fatty acids
in their tissues because they cannot produce ω-3 from ω-
6 fatty acids, while the fat-1 transgenic mice showed sig-
nificant amounts of ω-3 fatty acids in their tissues (1, and
see table 1 for differences in the ratio between ω-3 and ω-
6 fatty acids in various tissues between wild-type and fat-
1 mice). The transgenic mice were found to be normal and
healthy and many generations of transgenic mouse lines
have been examined and their tissue fatty acid profiles
showed consistently high levels of ω-3 fatty acids, indicat-
ing that the transgene is transmittable.
Preliminary studies have already confirmed that trans-
genic  fat-1  mouse is resistant to colitis [2], chemical-
induced hepatitis due to dampening of inflammatory
reaction [3] and post-ovariectomy osteoporosis [4]. Coli-
tis, chemical-induced hepatitis and osteoporosis are all
due to enhanced production of cytokines: inerleukin-6
(IL-6) and tumor necrosis factor-α (TNF-α) and since
these diseases are much less severe in transgenic fat-1
mouse indicates that presence of enhanced amounts of ω-
3 fatty acids in the respective tissues and plasma has a
dampening effect on inflammation. In all these studies
except in the colitis model study [2], plasma and tissue
levels of ω-3 fatty acid products lipoxins, resolvins, pro-
tectins and maresins were not estimated.
A striking reduction in melanoma development and pro-
gression in fat-1  transgenic mice in parallel with an
increase in the levels of PGE3 (prostaglandinE3) derived
from EPA and higher ω-3/ω-6 ratio in the tumor and sur-
rounding tissue of fat-1 mice compared to wild type ani-
mal was reported [5]. The PTEN (a tumor suppressor)
gene was significantly up-regulated in the fat-1 mice. We
propose that the beneficial actions seen in transgenic fat-
1  mouse with regard to less severe colitis, chemical-
induced hepatitis, osteoporosis and anti-cancer activity
are all due to enhanced formation of lipoxins, resolvins,
protectins and maresins derived from ω-3 EPA and DHA.
This implies that lipoxins, resolvins, protectins and mares-
ins have anti-atheroslcerotic, cardioprotective actions and
anti-cancer actions, especially following acute myocardial
infarction and ischemia-reperfusion injury.
Despite these benefits noted with the fat-1  transgenic
mice, it is not without side effects. Ji et al [6] developed
seven lines of fat-1 transgenic mice (C57/BL6) controlled
by the regulatory sequences of the adipocyte protein-2
(aP2) gene for adipocyte-specific expression (AP-lines). Ji
et al [6] were unable to obtain homozygous fat-1 trans-
genic offspring from the two highest expressing lines, sug-
gesting that excessive expression of this enzyme may be
lethal during gestation. As expected, it was noted that
serum fatty acid analysis of fat-1 transgenic mice (AP-3)
fed a high ω-6 unsaturated fat diet had a ω-6/ω-3 fatty acid
ratio reduced by 23% and the ω-3 fatty acid eicosapentae-
noic acid (EPA) concentration increased by 61%. Docosa-
hexaenoic acid (DHA) was increased by 19% in white
adipose tissue. Male AP-3-fat-1 line of mice had improved
glucose tolerance and reduced body weight with no
change in insulin sensitivity when challenged with a high-
carbohydrate diet, while the female AP-3 mice had
reduced glucose tolerance and no change in insulin sensi-
tivity or body weight. These findings indicate that male
transgenic  fat-1  mice have improved glucose tolerance
likely due to increased insulin secretion while female fat-
1 mice have reduced glucose tolerance compared to wild-
type mice. The inability of fat-1 transgenic mice to gener-
ate homozygous offspring suggests that prolonged expo-
sure to increased concentrations of ω-3 fatty acids may be
detrimental to reproduction [6].
Since some of the beneficial actions of PUFAs are attrib-
uted to the formation of anti-inflammatory molecules
The fat-1 gene encodes an n-3 desaturase that converts n-6  to n-3 fatty acid Figure 1
The fat-1 gene encodes an n-3 desaturase that con-
verts n-6 to n-3 fatty acid.
CH3-CH2-CH2-CH2-CH2-CH = CH-CH2-CH2---------------COOH   Ȧ-6 (18:2; 20:4; 22:4; 22:5) 
CH3-CH2-CH=CH-CH2-CH = CH-CH2-CH2----------------COOH   Ȧ-3 (18:3; 20:5; 22:5; 22:6) Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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derived from AA, EPA and DHA, it is pertinent to discuss
briefly here the metabolism of essential fatty acids.
Metabolism of essential fatty acids
Essential fatty acids (EFAs) are important constituents of
all cell membranes and confer on membranes properties
of fluidity and thus, determine and influence the behav-
iour of membrane-bound enzymes and receptors. EFAs
are essential and cannot be synthesized in the body and
hence, have to be obtained in our diet [7]. There are two
types of EFAs, the ω-6 series derived from cis-linoleic acid
(LA, 18:2) and the ω-3 series derived from α-linolenic acid
(ALA, 18:3). LA is converted to γ-linolenic acid (GLA,
18:3, n-6) by the action of the enzyme Δ6 desaturase (Δ6d)
and GLA is elongated to form dihomo-GLA (DGLA, 20:3,
n-6), the precursor of the 1 series of prostaglandins (PGs).
DGLA can also be converted to arachidonic acid (AA,
20:4, n-6) by the action of the enzyme Δ5 desaturase (Δ5
d). AA forms the precursor of 2 series of prostaglandins,
thromboxanes and the 4 series of leukotrienes. ALA is
converted to eicosapentaenoic acid (EPA, 20:5, n-3) by Δ6
and Δ5desaturases. EPA forms the precursor of the 3 series
of prostaglandins and the 5 series of leukotrienes. LA,
GLA, DGLA, AA, ALA, EPA and docosahexaenoic acid
(DHA, 22:6, n-3) are all PUFAs, but only LA and ALA are
EFAs (see Figure 2 for metabolism of EFAs). AA and EPA
also give rise to their respective hydroxy acids, which in
turn are converted to their respective leukotrienes (LTs).
Both PGs and LTs are highly biologically active and have
pro-inflammatory action, and are known to be involved
various pathological processes. Many of the functions of
EFAs are also brought about by PUFAs and EFA-deficiency
states can be corrected to a large extent by PUFAs.
Studies revealed that PUFAs themselves play a significant
role in the pathobiology of clinical conditions. This is in
addition to the role of PGs and LTs in these conditions.
For instance, in inflammatory bowel disease the inflam-
matory events seem to be initiated and perpetuated by
PGs and LTs (such as PGE2, PGF2α, TXA2 and LTB4, LTC4,
and LTD4) produced from AA, whereas when significant
amounts of EPA and DHA are given the inflammatory
process is abrogated to a large extent. This beneficial
action of EPA/DHA when supplemented from external
sources has been attributed to the displacement AA from
the cell membrane phospholipid pool and to the forma-
tion of less pro-inflammatory PGs (such as PGE3, PGF3α,
TXA3), and LTs (such as LTB5, LTC5, and LTD5) from them
and hence the favorable response (see Figure 2 for metab-
olism of EFAs and various products formed from them).
AA, EPA and DHA also give rise to anti-inflammatory
molecules such as lipoxins (LXs), resolvins, protectins and
maresins and nitrolipids. LXs, resolvins, protectins and
maresins (see Figure 2 for metabolism of essential fatty
acids and the formation of resolvins, protectins, lipoxins
and maresins from PUFAs) suppress inflammation and
help in the resolution of inflammatory events including
leukocyte infiltration and clearance of the cellular debris
from the site of inflammation. This suggests that PUFAs
form precursors to both pro- and anti-inflammatory mol-
ecules and the balance between these mutually antagonis-
tic compounds could determine the final outcome of the
disease process that forms the basis of generating fat-1
mice and favorable results seen with fat-1 mice [1-6].
EFAs and PUFAs play a significant role in various diseases
and especially in cardiovascular and neurological/psychi-
atric disorders [8-15]. This is in addition to the role of PGs
and LTs in these conditions. AA, EPA and DHA give rise to
anti-inflammatory molecules lipoxins (LXs), resolvins,
protectins and maresins that suppress inflammation.
Thus, PUFAs form precursors to both pro- and anti-
inflammatory molecules and the balance between these
mutually antagonistic compounds could determine the
final outcome of the disease process. Biologically active
compounds formed due to the nitration of unsaturated
fatty acids called as nitrolipids have also been identified.
Nitrolipids stimulate smooth muscle relaxation, block
platelet activation, inhibit human neutrophil functions
and suppresses inflammation. Thus, PUFAs have many
important actions not only by themselves but also by giv-
ing raise to various biologically active compounds.
-6 and  -3 balance and their role in cardiovascular, 
neurological and psychiatric disorders
It has been suggested that a substantial fall in the intake of
ω-3 fatty acids could be one of the major changes in West-
ern nutrition in the last 50 years that contributed to the
increasing incidence of cardiovascular and neurological/
psychiatric disorders. By increasing the intake of either ω-
6 or ω-3 fatty acids, the plasma and tissue content of these
fatty acids could be enhanced. In general, an increase in
the content of ω-6 fatty acids such as AA is expected to lead
an increase in the formation of pro-inflammatory PGs,
Table 1: Fatty acid ratio ( -6/ -3) in wild-type and fat-1 mice.
-6/ -3 ratio
Tissue Wild-type fat-1
Muscle 49.0 0.7
Milk 32.7 5.7
RBC 46.6 2.9
Heart 22.8 1.8
Brain 3.9 0.8
Liver 26.0 2.5
Kidney 16.5 1.7
Lung 32.3 2.2
Spleen 23.8 2.4Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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Scheme showing the metabolism of essential fatty acids Figure 2
Scheme showing the metabolism of essential fatty acids.
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LTs and TXs; whereas an increase in the content of ω-3
fatty acids such as EPA and DHA could lead to enhanced
formation of less pro-inflammatory compounds such as
PGI3, TXA3, LTs of 5 series and anti-inflammatory com-
pounds lipoxins, resolvins, protectins and maresins that
can prevent or even resolve the development of athero-
sclerosis, coronary heart disease, hypertension, Alzhe-
imer's disease, schizophrenia, depression, Huntington's
disease and other cardiovascular and neurological dis-
eases that are associated with inflammatory events. In
view of this, it has been recommended that both normal
individuals and subjects who are at high risk of develop-
ing these diseases and patients enhance their intake of ω-
3 fatty acids especially EPA and DHA.
Mammals cannot convert ω-6 to ω-3 fatty acids since they
lack the gene for this purpose. Using transgenic approach,
Kang et al (1) heterologously expressed the C. elegans fat-
1  gene in mice. The resultant mice not only showed
enhanced concentrations of ω-3 ALA, EPA, DHA, and
docosapentaenoic acid (DPA), but also significantly
reduced ω-6 LA and AA in muscle, red blood cells, heart,
brain, liver, kidney, lung, and spleen tissues such that the
ratio of ω-6 to ω-3 dropped from 20-50 to almost 1.
Despite such a drastic change in the ratio of ω-6 to ω-3 the
transgenic mice were found to be normal and healthy
though they showed inability to generate homozygous
offspring [6]. The fat-1 transgenic mouse model is ideal to
study the effects of tissue ω-6/ω-3 ratio in the body and to
delineate the exact molecular mechanism of actions of ω-
3 fatty acids and their metabolites.
ω-6 and  ω-3 imbalance in cardiovascular diseases
EFAs and their long-chain metabolites such as GLA,
DGLA, AA, EPA and DHA and other products such as
prostaglandins E1  (PGE1), prostacyclin (PGI2), PGI3,
lipoxins (LXs), resolvins, protectins and maresins prevent
platelet aggregation, lower blood pressure, have anti-
arrhythmic action, reduce LDL-C, ameliorate the adverse
actions of homocysteine, show anti-inflammatory
actions, activate telomerase, and have cytoprotective
properties. Of all the PUFAs: DHA = EPA > GLA > DGLA
when their actions on platelet aggregation, ability to lower
blood pressure, prevent cardiac arrhythmias, reduce LDL-
C, ameliorate the adverse actions of homocysteine, anti-
inflammatory action, activation of telomerase and cyto-
protective properties are compared. On the other hand,
AA may enhance the production of pro-inflammatory
eicosanoids and thus, could be harmful though it should
be noted that anti-inflammatory compounds such as
lipoxins are also formed from AA. Hence, the biological
actions of AA in the body seem to be rather tricky. Under
certain circumstance, AA may actually be beneficial by giv-
ing rise to lipoxins whereas at times it may be harmful by
increasing the production of pro-inflammatory eicosa-
noids. Several studies showed that in patients with CHD,
hypertension and type 1 and type 2 diabetes mellitus,
plasma and tissue levels of AA have been shown to be low
(reviewed in [15-17]) suggesting that perhaps in these
conditions enhancing the tissue and plasma levels of AA
could be beneficial. It has not been shown but, it is possi-
ble that when plasma and tissue levels of AA are normal
the formation of lipoxins could be optimum such that
inappropriate platelet aggregation, atherosclerosis and
inflammation would not occur. Thus, under physiological
conditions EFAs and their metabolites show all the classic
actions expected of the "polypill" [17]. Furthermore, EFAs
are endogenous molecules present in almost all tissues,
have no significant or few side effects, can be taken orally
for long periods of time even by pregnant women, lactat-
ing mothers, and infants, children, and adults; and reduce
the incidence of cardiovascular diseases including stroke.
In addition, various EFAs and their long-chain metabo-
lites (including lipoxins, resolvins, protectins and mares-
ins) not only enhance nitric oxide generation but also
react with nitric oxide to yield their respective nitroalkene
derivatives that produce vascular relaxation, inhibit neu-
trophil degranulation and superoxide formation, inhibit
platelet activation, and possess PPAR-γ ligand activity and
release NO, thus prevent platelet aggregation, thrombus
formation, atherosclerosis, and cardiovascular diseases.
These evidences suggest that a rational combination of ω-
3 and ω-6 fatty acids and the co-factors that are necessary
for their appropriate action/metabolism is as beneficial as
that of the combined use of a statin, thiazide, a β blocker,
and an angiotensin converting enzyme (ACE) inhibitor,
folic acid, and aspirin. Furthermore, appropriate combi-
nation of ω-3 and ω-6 fatty acids may even show addi-
tional benefits in the form of protection from depression,
schizophrenia, Alzheimer's disease, and enhances cogni-
tive function; and serve as endogenous anti-inflammatory
molecules; and could be administered from childhood for
life long [17].
Based on these evidences, it is suggested that studies can
be performed in transgenic fat-1 mouse to verify some of
the above postulations. For instance, we hypothesize that
transgenic fat-1 mouse will be resistant to atherosclerosis,
thrombosis, CHD, stroke and inflammatory conditions
such as inflammatory bowel diseases, collagen vascular
diseases such as rheumatoid arthritis and lupus, ischemia-
reperfusion injury, and cardiac arrhythmias following
myocardial infarction.
Preliminary studies have already confirmed that trans-
genic fat-1 mouse is indeed resistant to colitis (2), chemi-
cal-induced hepatitis due to dampening of inflammatory
reaction (3) and post-ovariectomy osteoporosis (4). Coli-
tis, chemical-induced hepatitis and osteoporosis are due
to enhanced production of pro-inflammatory cytokines.Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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Since these diseases are much less severe in transgenic fat-
1 mouse indicates that presence of enhanced amounts of
ω-3 fatty acids in the respective tissues and plasma has a
dampening effect on inflammation. In all these studies
except in the colitis model study (2), plasma and tissue
levels of ω-3 fatty acid products lipoxins, resolvins, pro-
tectins and maresins were not estimated. We propose that
the beneficial actions seen in transgenic fat-1 mouse with
regard to less severe colitis, chemical-induced hepatitis
and osteoporosis are due to enhanced formation of lipox-
ins, resolvins, protectins and maresins derived from ω-3
EPA and DHA.
-6 and  -3 imbalance and schizophrenia, Huntington's 
disease, and Alzheimer's disease
Low-grade systemic inflammation plays a significant role
in the pathobiology of schizophrenia, Huntington's dis-
ease, depression and Alzheimer's disease. In patients with
schizophrenia, both circulating and cerebrospinal fluid
(CSF) concentrations of pro-inflammatory cytokines are
increased and the plasma phospholipid concentrations of
EPA and DHA are decreased. Supplementation of EPA
(especially ethyl EPA) was reported to be of some benefit
to these patients (reviewed in [11-14]).
Diet high in DHA slowed the progression of Alzheimer's
disease (AD) in mice. Specifically, DHA cut the harmful
brain plaques that mark the disease. Mice genetically
altered to develop Alzheimer's disease, when were fed
with DHA-fortified chow had 70-percent less buildup of
amyloid protein in the brain compared with control or
DHA-deficient mice (14, 18-20). DHA protected against
damage to the "synaptic" areas and enabled mice to per-
form better on memory tests.
An inverse relationship has been found between transthy-
retin CSF level, an amyloid plaque scavenger, and the
severity of dementia in AD patients [21]. In response to
diet having high concentration of ω-3 in old rat hippoc-
ampus the expression of the transthyretin gene was dra-
matically induced [22], suggesting a positive role of ω-3 in
AD patients. On the other hand, our data on the perinatal
influence of dietary ω-3 depletion and the expression of
the ZnT3 in the brain (and subsequent sequestration of
zinc into brain tissue) could provide an important link
between the positive effects of dietary DHA and reduced
brain zinc on the pathology of AD [23]. It would be inter-
esting to study the brain zinc distribution in the fat-1
transgenic mouse brain.
These studies indicate that increased intake of DHA could
be of benefit in people who are genetically or otherwise
predisposed to develop the disease. Furthermore, recent
studies [24] in fat-1 transgenic mice showed that increased
brain DHA significantly enhances hippocampal neuro-
genesis as evidenced by an increase in the number of pro-
liferating neurons and increased density of dendritic
spines of CA1 pyramidal neurons in the hippocampus.
Concurrently, fat-1 mice exhibited a better spatial learning
performance in the Morris water maze compared with
control WT (wild-type) littermates. In vitro experiments
further demonstrates that DHA promotes differentiation
and neurite outgrowth of neuronal cells derived from
mouse ES cells and increases the proliferation of cells
undergoing differentiation into neuronal lineages from
the ES cells. These results provide direct evidence that
DHA promotes neurogenesis and neuritogenesis and
thus, ω-3 fatty acids are beneficial in the prevention and
treatment of Alzheimer's disease and improve behavioral
performance.
Huntington's disease is an inherited neurodegenerative
disorder due to a mutation in exon 1 of the Huntingtin
gene that encodes a stretch of polyglutamine (poly Q) res-
idues close to the N-terminus of the Huntingtin protein.
Aggregated poly Q residues are toxic to the neuronal cells.
Transgenic R6/1 mice that develop late-onset neurologic
deficits similar to the motor abnormalities of Hunting-
ton's disease seen in humans showed increased survival
rates and decreased neurologic deficits when were supple-
mented with PUFAs, especially ethyl EPA [13], suggesting
that unsaturated fatty acids may prevent or arrest poly Q
aggregation. These results suggest that PUFAs, in general,
are useful in the treatment of various neurological dis-
eases. Some of the beneficial actions of these PUFAs in
neurological diseases could be due to the increased forma-
tion of lipoxins and resolvins that have neuroprotective
actions. But, it is not clear why and how a particular fatty
acid is useful only in a specific neurological condition. For
instance, DHA is useful in Alzheimer's disease whereas
ethyl EPA is of benefit in Huntington's disease and schiz-
ophrenia. More research is needed to understand the
molecular mechanisms of action of EPA/DHA in these
neurological conditions.
These evidences suggest that increased intake of EPA/DHA
may prevent Alzheimer's disease, schizophrenia and
Huntington's disease. Even after the onset of the disease,
supplementation of EPA/DHA appears to either prevent
further progression or even reverse some of the features of
these diseases. Since transgenic fat-1 mouse is able to con-
vert ω-6 to ω-3 fatty acids and thus, contain significantly
higher amounts of EPA/DHA in several tissues including
brain, we hypothesize that Alzheimer's disease, schizo-
phrenia, depression and Huntington's disease are unlikely
to occur in this mouse model or even if they occur they
will be of less severity. Hence, it is important to study in
the transgenic fat-1  mouse model what metabolites of
EPA/DHA are responsible for their protective action
against Alzheimer's disease, schizophrenia, depression
and Huntington's disease. It is highly likely that lipoxins,
protectins, resolvins and maresins are formed in signifi-Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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cantly higher amounts in the transgenic fat-1 mouse that
accounts for the beneficial actions of EPA/DHA.
Actions of EFAs and their metabolites that could account 
for their beneficial actions
Cell membrane fluidity
Cell membrane fluidity is determined by its lipid compo-
sition: increasing its content of saturated fatty acids and
cholesterol renders the membrane more rigid, whereas
increasing unsaturated fatty acids makes it more fluid.
This is an important function of lipids since the number
of receptors and their affinity to their respective hor-
mones/growth factors/proteins depends on the fluidity of
the cell membrane.
Availability of appropriate amounts of ω-3 and ω-6 fatty
acids and various growth factors is essential for the growth
of brain during the perinatal period and adolescence
[7,11-13,24-26]. Deficiency of ω-3 EPA and DHA and ω-6
AA during the critical growth period impairs brain growth
and the development of appropriate synaptic connections
that, in turn, could lead to developmental disorders of the
brain and neuropsychological conditions: dementia,
depression, schizophrenia, Alzheimer's disease, and neu-
rodegenerative diseases: Huntington's disease, Parkin-
son's disease, spinocerebellar degeneration, etc, and may
impair memory formation and consolidation. We suggest
that the fluidity of the cell membranes of the neurons and
other cells in transgenic fat-1 mouse will be more fluid
compared to wild type mouse. The increase in cell mem-
brane fluidity will enable growth factors and neurotrans-
mitters to bind to their respective receptors with high
affinity that may protect transgenic fat-1 mouse against
Alzheimer's disease, schizophrenia and Huntington's dis-
ease.
We found that combined application of cholesterol a
compound that makes membranes more rigid and PUFA
that increase the fluidity of biological membranes had dif-
ferent effects on inflammatory gene expressions in brain
and in the eye [21-23]. We hypothesize that in the fat-1
transgenic mouse cholesterol has much less negative
effects than in the wild-type mouse.
Endothelial nitric oxide generation
EPA/DHA enhances endothelial nitric oxide generation
[27]. Plasma and tissue concentrations of PUFA and eNO
are low in dementia, schizophrenia, bipolar disorders,
Huntington's disease and Alzheimer's disease [7,11-
13,18-20,27,28].
NO is a potent anti-atherosclerotic and anti-inflammatory
molecule. Aspirin enhances the formation of eNO
through the generation of epi-lipoxins that may explain
its anti-inflammatory action [29]. Epi-lipoxins that have
potent anti-inflammatory actions and enhance the gener-
ation of NO, whereas NO stimulates the formation of
PGI2 from AA [30] and lipoxins are derived from AA, EPA,
and DHA. These results emphasize the close interaction
between PUFAs, NO synthase, and COX enzymes [31].
Furthermore, PUFAS can react with NO to form nitrolip-
ids that can release NO. Based on these results, we pro-
pose that transgenic fat-1  mouse produce increased
amounts of eNO, PGI2 and PGI3 and lipoxins compared to
the wild-type that could also account for the decreased
incidence of various cardiovascular and neurological and
psychiatric disorders.
Suppression of production of pro-inflammatory cytokines
EPA, DHA, LXs, resolvins, protectins and maresins sup-
press pro-inflammatory IL-1, IL-2, IL-6, macrophage
migration inhibitory factor (MIF), HMGB1 (high mobility
group box 1) and TNF-α production by T cells and other
cells (7, 32-35), and thus could function as endogenous
anti-inflammatory molecules. PGE2, PGF2α, TXA2 and LTs
derived from AA also modulate IL-6 and TNF-α produc-
tion. These results imply levels of IL-6 and TNF-α at the
sites of inflammation and injury may depend on the local
levels of various PUFAs and eicosanoids formed from
them. The ability of EPA and DHA to suppress the produc-
tion of pro-inflammatory cytokines and induce their anti-
inflammatory actions are mediated by their ability to
increase PPAR-γ mRNA and protein activity [35].
IL-1, IL-6, MIF (macrophage migration inhibitory factor)
and TNF-α induce insulin resistance, have cytotoxic
actions, are neurotoxic, and seem to have a role in the
pathobiology of cardiovascular and neurologic and psy-
chiatric conditions. Hence, we predict that in transgenic
fat-1  mouse the production of pro-inflammatory
cytokines will be low compared to the wild type.
HMG-CoA reductase activity
Similar to statins, EPA and DHA are useful in the treat-
ment of hyperlipidemias. More importantly, EPA and
DHA are potent inhibitors of the HMG-CoA reductase
enzyme [36,37]. Statins enhance plasma PUFA concentra-
tions and decrease the ratio of EPA to AA significantly
[38].
PUFAs down regulate hepatic cholesterol synthesis by
impairing the SREBP (sterol regulatory element-binding
protein) pathway; reduce SREBP-mediated gene transcrip-
tion by increasing intracellular cholesterol content
through the hydrolysis of cellular sphingomyelin;
decrease SRE-mediated gene transcription of SREBP-1 and
SREBP-2 and thus, PUFAs modulate the function of
SREBPs [39-43].
HMG-CoA reductase catalyzes the synthesis of meval-
onate, which is the rate-limiting step in the mevalonate
pathway. Mevalonate is the precursor of cholesterol and aLipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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variety of isoprenoid containing compounds. These iso-
prenoid precursors are necessary for the posttranslational
lipid modification (prenylation) and hence, the function
of  Ras  and other small GTPases. Hence, inhibition of
mevalonate pathway has the potential to disrupt the func-
tion of oncogenic forms of Ras. This explains the ability of
PUFAs, especially EPA and DHA to suppress Ras activity,
anti-proliferative action and induce apoptosis of tumor
cells. Small GTPases, which are prenylated products of the
mevalonate pathway, have negative control on the expres-
sion of BMPs (bone morphogenetic proteins). Thus, inhi-
bition of the mevalonate pathway by EPA and DHA will
prevent the function of small GTPases that, in turn,
enhances the expression of various BMPs. BMPs are essen-
tial for neuronal growth, proliferation, and differentia-
tion. Thus, EPA and DHA modulate brain growth and
development, and neuronal differentiation. This action is
in addition to their (EPA and DHA) ability to form an
important constituent of neuronal cell membranes and
involvement in memory formation and consolidation
[24-26], explaining the beneficial action of EPA and DHA
in the prevention and treatment of dementia and Alzhe-
imer's disease [18-20,24-26,44,45]. In addition, the bene-
ficial action of EPA and DHA in Alzheimer's disease,
schizophrenia and dementia can also be attributed to the
formation of anti-inflammatory compounds such as
lipoxins, resolvins, protectins and maresins from EPA and
DHA.
Based on these evidences, we propose that in transgenic
fat-1 mouse will not only have increased amounts of EPA
and DHA in the brain and other tissues and plasma but
also show reduced activity of HMG-CoA reductase
enzyme, altered SREBP-mediated gene transcription,
decreased  Ras  activity and enhanced levels of various
BMPs in the brain.
Conclusions
It is evident from the preceding discussion that EFAs and
their metabolites including eicosanoids, LXs, resolvins,
protectins and maresins and nitrolipids have many bio-
logical actions and are beneficial in the prevention of car-
diovascular and neurological/psychiatric disorders. Since
transgenic fat-1 mouse have increased concentrations of
EPA and DHA in the brain and other tissues and plasma,
we suggest that in this animal model the production of
pro-inflammatory cytokines will be low; plasma and tis-
sue concentrations of pro-inflammatory eicosanoids will
be low with a simultaneous increase in the formation of
anti-inflammatory compound such as lipoxins, pro-
tectins, resolvins and maresins; the cell membrane will be
highly fluid with decreased HMG-CoA reductase activity
and enhanced activity of eNOS; altered expression of
genes for SREBPs; decreased Ras activity and high concen-
trations of various BMPs. In addition, we also propose
that the expression of uncoupling protein-1 (UCP-1) in
the vascular tissue and the expression of adhesion mole-
cules (integrins) will be low and thus, the occurrence of
atherosclerosis will be decreased in transgenic fat-1
mouse. In a recent study, we showed that in fat-1 trans-
genic mouse the expression of several genes concerned
with inflammation, apoptosis, cell cycle, neurotransmit-
ters, and hormones are altered [46] (see Tables 2 and 3).
Thus, in transgenic fat-1 mouse there will be significant
alterations in the concentrations and expression of
cytokines, pro-inflammatory eicosanoids, insulin, neuro-
transmitters, PLA2, sphingosine kinase, caspases, far-
nesoid X receptor, PPARs, SREBPs, HMG-CoA reductase,
transforming growth factor, cytokeratins, and nitric oxide
synthase ([15,47-50] and see Table 4) that accounts for
the decreased incidence of cardiovascular and neurologi-
cal and psychiatric disorders (see Figure 3).
In addition, recent studies showed that DHA yields an
array of potentially bioactive lipid compounds such as
cyclopentenone isoprostanes and cyclopentenone neuro-
prostanes (A(4)/J(4)-NPs), which are highly reactive and
similar in structure to anti-inflammatory cyclopentenone
prostaglandins. The synthetic A(4)/J(4)-NP, 14-A(4)-NP
(A(4)-NP), potently suppressed lipopolysaccharide-
induced expression of inducible nitric-oxide synthase,
cyclooxygenase-2, NF-kappaB activation via inhibition of
Ikappa kinase-mediated phosphorylation of IkappaBal-
pha in macrophages. The effects of A(4)-NP were found to
be independent of peroxisome proliferator-activated
receptor-γ (PPAR-γ) and were dependent on an intact reac-
tive cyclopentenone ring. Paradoxically, free radical-medi-
ated oxidation of DHA greatly enhanced its anti-
inflammatory potency, an effect that closely parallels the
formation of A(4)/J(4)-NPs. Furthermore, chemical
reduction or conjugation to glutathione, both of which
eliminate the bioactivity of A(4)-NP, also abrogated the
anti-inflammatory effects of oxidized DHA. Thus, A(4)/
J(4)-NPs, formed via the oxidation of DHA, are potent
inhibitors of NF-kappaB signaling and contribute to the
anti-inflammatory actions of DHA [51,52], suggesting
that the anti-inflammatory properties of ω-3 fatty acids
are closely associated and dependent on the novel interac-
tions between lipid peroxidation products and inflamma-
tion. It is interesting to note that cyclopentenone
isoprostanes (IsoPs), highly reactive structural isomers of
the bioactive cyclopentenone prostaglandins PGA2 and
PGJ2, are formed non-enzymatically as products of oxida-
tive stress in vivo and 15-A2-IsoPs induced oxidative stress
to inhibit the NF-kappaB pathway at least partially via a
redox-dependent mechanism. 15-J2-IsoP induced RAW
cell apoptosis again via a PPAR-γ-independent mecha-
nism. These findings suggest that oxidative stress is bene-
ficial at times by inducing the formation of
cyclopentenone IsoPs that may serve as negative feedback
regulators of inflammation [52,53].Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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Scheme showing the relationship among PUFAs and cardiovascular and neurological conditions Figure 3
Scheme showing the relationship among PUFAs and cardiovascular and neurological conditions.
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It may be mentioned here that the beneficial actions of
DHA and EPA in neurological conditions described above
is not without controversy. For instance, Bate et al [54,55]
reported that pre-treatment with DHA or EPA significantly
reduced the survival of cortical or cerebellar neurons incu-
bated with HuPrP82-146, a peptide derived from the
prion protein, or with Abeta 1-42, a peptide found in
Alzheimer's disease. They noted that treatment with DHA
or EPA reduced the free cholesterol content of neuronal
membranes that increased the kinetics of incorporation.
In untreated neurons, FITC-HuPrP82-146 migrated to
caveolin-1 containing lipid rafts, triggered the migration
of cytoplasmic phospholipase A2 (cPLA2) into caveolin-1
containing rafts, and increased prostaglandin E2 produc-
tion. They also observed that the activation of cPLA2 and
prostaglandin E2 production were both increased in neu-
rons pre-treated with DHA, suggesting that DHA or EPA
alter cell membrane fluidity that could result in increased
amounts of HuPrP82-146 localizing to caveolin-1 con-
taining rafts, increased activation of cPLA2, prostaglandin
E2 production, caspase-3 activity and reduced neuronal
survival. These observations indicate that under some spe-
cific conditions ω-3 fatty acids EPA and DHA may actually
accelerate neuronal loss in the terminal stages of prion or
Alzheimer's diseases. This study suggests that further stud-
ies are needed to understand the close interaction
between ω-3 fatty acids and free radicals and the series of
products formed and the exact sequence of formation of
various anti- and pro-inflammatory products that ulti-
mately determine the neuronal loss or their growth. It is
possible that under low oxidative stress conditions bene-
ficial products such as lipoxins, resolvins, protectins,
maresins, isoprostanes and A(4)/J(4)-NPs are formed and
under excessive oxidative stress conditions cPLA2 is acti-
vated leading to the formation of PGE2 leading to neuro-
nal loss (see Figure 2).
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Table 2: Genes whose expression is altered in transgenic fat-1 mouse (see Ref. [46]).
Genes whose expression is down-regulated Genes whose expression is up-regulated
Stearoyl-Coenzyme A desaturase 2 (Scd2) Hydroxysteroid dehydrogenase-2, delta<5>-3-beta (Hsd3b2)
Prostaglandin D2 synthase (brain) (Ptgds) Signal-induced proliferation-associated 1 like 1 (Sipa1l1)
Purkinje cell protein 4 (Pcp4) Calpain 1 (Capn1)
Heat shock protein 2 (Hspb2) Chloride channel calcium activated 6 (Clca6)
Apolipoprotein D (Apod) Dopamine receptor D1 interacting protein (Drd1ip)
Sphingosine kinase 1 (Sphk1), transcript variant 2 Transforming growth factor, beta receptor II (Tgfbr2)
Low density lipoprotein receptor-related protein 1 (Lrp1) 3-hydroxy-3-methylglutaryl-Coenzyme A lyase (Hmgcl)
Lysophosphatidylglycerol acyltransferase 1 (Lpgat1)
Phospholipase A2, group IVE (Pla2g4e)
Dopamine receptor 4 (Drd4)
DnaJ (Hsp40) homolog, subfamily C, member 5 (Dnajc5)
Solute carrier family 32 (GABA vesicular transporter), (Slc32a1)
Basal cell adhesion molecule (Bcam), mRNA
Chemokine (C-C motif) receptor 5 (Ccr5), mRNA
Peroxisomal biogenesis factor 11a (Pex11a)
Heat shock protein 1, beta (Hspcb)
Gamma-aminobutyric acid (GABA-A) receptor, beta 3 (Gabrb3)Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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Table 3: Proteins that are either upregulated or downregulated 
in the brain of fat-1 transgenic mouse (see Ref. [46]).
Down-regulated proteins Fold change
Caspase 4 -1.74
Connexin 32 -1.71
HSP70 -1.69
cytokeratin 19 -1.64
cytokeratin 8.12 -1.63
TRF1 -1.59
cdk6 -1.56
Desmin -1.54
cytokeratin 13 -1.48
cytokeratin 7 -1.46
Calmodulin -1.46
pan Cytokeratin -1.45
Nedd8 -1.43
aCatenin -1.43
NTF2 -1.38
Dystrophin -1.38
Up-regulated proteins Fold change
Phospolipase A2 group V 1.40
FAK Phospo (pY577) 1.45
Nicastrin 1.46
b-NOS 1.46
CRK-L 1.47
S-100 1.47
SGK 1.48
Caveolin1 1.49
Bcl-xl 1.50
ARTS 1.50
i-NOS 1.51
CAM Kinase IV 1.52
PTEN 1.52
PAR4 1.52
Neurofilament 200 1.54
Gamma Tubulin 1.56
MAP Kinase(Erk1) 1.56
Phospolipase c gamma 1 1.56
MAPK activated protein kinase-2 1.56
EGF receptor 1.58
MAP Kinase activated phospotyrosine 1.58
ERK5 1.58
Protein phosphatase 1 1.60
p35 1.60
PAK phospo (Ps212) 1.60
PKC alfa 1.62
PKD 1.62
Glutamate receptor NMDAR 2a 1.63
S-100 beta 1.63
Protein phosphatase 1 1.64
FAK Phospo (pS772) 1.65
DOPA Decarboxylase 1.66
PKC gamma 1.66
NFKB 1.67
JNK activated diphospo 1.69
Tau Phospho (pS199/202) 1.79
Synuclein monoclonal 1.79
Estrogen Receptor 1.81
GRB-2 1.95
MAP Kinase activated phospothreonine 1.98
Table 3: Proteins that are either upregulated or downregulated 
in the brain of fat-1 transgenic mouse (see Ref. [46]). (Continued)Lipids in Health and Disease 2009, 8:61 http://www.lipidworld.com/content/8/1/61
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Table 4: Proposed differences between the wild type and Fat-1 mouse.
Parameter Wild type Fat-1 mouse
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